サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：スコポラミンの世界市場-2022-2029
市場調査レポート
商品コード
1153801

スコポラミンの世界市場-2022-2029

Global Scopolamine Market - 2022-2029
出版日: | 発行: DataM Intelligence | ページ情報: 英文 180 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.97円
スコポラミンの世界市場-2022-2029
出版日: 2022年11月15日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場の概要

スコポラミンは、一般的にヒヨスチンとして知られており、天然または合成で製造されるトロパンアルカロイドおよび抗コリン作用のある薬物です。正式には、乗り物酔いや術後の吐き気・嘔吐の治療に使用されます。また、スコポラミンは、痙攣性筋疾患、憩室炎、過敏性腸症候群、パーキンソン様症状など、胃や腸の問題を治療することもあります。

市場力学

世界のスコポラミン市場を牽引する主な要因は、消化器系だけでなく、消化器官に影響を与える食習慣やカジュアルなライフスタイルです。スコポラミンは急性めまいの治療に使用され、めまいの有病率を高め、また市場の成長に貢献し、さらに心理的ストレスは乗り物酔いの重要な要因の1つに考えられています。

世界のがんの増加により、市場の成長が見込まれています。

WHOの統計によると、2020年の死亡者数は1,000万人で、約6人に1人ががんで死亡しているとされています。そのうち、約70％は低・中所得国で発生しており、最も多いのは乳がん（2020年226万件）、肺がん（2020年約221万件）、結腸・直腸がん（2020年193万件）です。そのため、化学療法が増加し、スコポラミン製剤の需要につながっています。したがって、上記の要因から、予測期間において市場の成長を牽引することが期待されます。

スコポラミン薬の副作用や製品廃止は、市場成長の妨げになると予想されます。

しかし、スコポラミンの副作用や特定の市場関係者による製品の製造中止は、予測期間中の世界のスコポラミン市場の成長を阻害します。例えば、スコポラミンには、アジテーション、瞳孔（目の黒い部分）の拡張、拡大、かすみ目などの一般的ではない副作用、混乱、光に対する目の感度上昇として一般的なものがあります。さらに、ペリゴ社は経営上の理由からスコポラミン経皮吸収システムの販売を中止したため、予測期間中に世界のスコポラミン市場の成長を鈍化させることになりました。

COVID-19の影響分析

現在進行中のCOVID-19の大流行は、慢性疾患に起因する外科手術の数の減少により、世界のスコポラミン市場に悪影響を与えています。例えば、2020年5月の国立生物工学情報センターの統計によると、外科手術は、危機を管理するためのすべての特別なルールによって大きな影響を受けました。パンデミックは、作業方法、手術手順、低侵襲手術、劇場のワークフロー、患者とスタッフの安全、トレーニング、教育などに影響を与えました。一方、外科チームは、可能な限り電話やビデオ診察を行い、必要のない経過観察は中止して、患者との関わりを減らすよう奨励されました。その結果、手術の回数は減り、麻酔、麻薬性鎮痛剤、手術後の吐き気や嘔吐を防ぐために使用されていたスコポラミン経皮パッチの必要性も減りました。

目次

第1章 調査手法と調査範囲

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場影響要因
    • 促進要因
      • 世界のがん罹患率の増加が市場成長の原動力になると予想されます。
    • 抑制要因
      • スコポラミン製剤の副作用と製品廃止が市場成長の妨げになると予想されます。
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターの5つの力
  • サプライチェーン
  • プライシング分析

第6章 COVID-19の分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、または将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的な取り組み
  • まとめ

第7章 剤形別

  • 錠剤
  • シロップ剤
  • 経皮吸収型テープ製剤
  • 注射剤
  • その他

第8章 アプリケーション別

  • 吐き気
  • 乗り物酔い

第9章 流通チャネル別

  • 病院内薬局
  • 小売薬局
  • オンライン薬局
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A（合併・買収）分析

第12章 企業プロファイル

  • Baxter International Inc.
    • 企業概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • GlaxoSmithKline plc.
  • Novartis AG
  • Perrigo Company plc.
  • Caleb Pharmaceuticals, Inc.
  • Myungmoon Pharma Co. LTD.
  • Alchem International
  • Phytex Australia
  • Centroflora-Cms
  • Alkaloids of Australia
  • Fine Chemical Corporation

第13章 世界のスコポラミン-DataM

目次
Product Code: DMPH738

Market Overview

The global scopolamine market size was valued around US$ YY million in 2021 and is expected to reach US$ YY million by 2029, growing at a CAGR of YY% during the forecast period (2022-2029).

Scopolamine, commonly known as hyoscine or devil's breath, is a tropane alkaloid and anticholinergic medication that is naturally or synthetically manufactured. It is formally used to treat motion sickness and postoperative nausea and vomiting. Scopolamine may also treat stomach or intestine issues such as spastic muscular states, diverticulitis, irritable bowel syndrome, and Parkinson-like symptoms.

Market Dynamics

Major factors driving the global scopolamine market are food habits and casual lifestyles, which affect the digestive system as well as the gastrointestinal system; scopolamine is used to treat acute vertigo, increase the prevalence of dizziness, also helps in market growth, and even psychological stress is considered to one of the significant contributor to motion sickness.

The increasing prevalence of cancer worldwide is expected to drive market growth.

According to the WHO statistics, cancer accounted for ten million deaths in the year 2020, about 1 in 6 deaths from cancer. Out of which, around 70% of deaths occurred in low- and middle-income countries; the most common type of cancer are breast (2.26 million cases in 2020), lung (around 2.21 million cases in 2020), and colon & rectum cancers (1.93 million cases in 2020). Therefore, it has led to an increase in chemotherapy, which led to the demand for scopolamine drugs. Thus, from the above factors, the market is expected to drive market growth in the forecast period.

Side effects and product discontinuation of scopolamine drugs are expected to hamper market growth.

However, the side effects of scopolamine and product discontinuation by certain market players hamper the global scopolamine market growth during the forecast period. For instance, scopolamine has common as Agitation, less common side effects such as dilated, bigger, or enlarged pupils (black part of the eye), blurred vision or other changes in vision, confusion, and increased sensitivity of the eyes to light. Furthermore, Perrigo has discontinued the scopolamine transdermal system due to business reasons, thus, slowing the global scopolamine market growth during the forecast.

COVID-19 Impact Analysis

The ongoing COVID-19 pandemic has negatively impacted the worldwide scopolamine market, owing to a decline in the number of surgical operations resulting from chronic conditions. For instance, according to National Center for Biotechnology Information statistics in May 2020, the surgical practice was greatly impacted by all special rules to manage the crisis. The pandemic impacted working methods, surgical procedures, minimally invasive surgery, theatre workflow, patient and staff safety, training, and education. In contrast, surgical teams were encouraged to offer phone or video consultations wherever possible and cancel non-essential follow-ups to reduce patient interaction. As a result, the number of surgery procedures was reduced, as was the necessity for the scopolamine transdermal patch, which was used to prevent nausea and vomiting following anesthesia, narcotic pain medications, and surgery.

Segment Analysis

Transdermal Patches segment is expected to hold the largest market share in scopolamine

The transdermal patches segment accounted for the largest market share in 2021. The segment benefits because they are preferred for their ease of use, low cost, and availability. The patch is placed behind the ear on the hairless skin and is used to relieve motion sickness caused by anesthetic during surgery. Furthermore, transdermal scopolamine can be eliminated from the body when it is no longer needed. For instance, Novartis AG, Transderm Scop (scopolamine) TRANSDERMAL SYSTEM 1.5 mg is a prescription drug used to treat the symptoms of vomiting caused by motion sickness from anesthesia. Therefore, it has increased the demand for scopolamine transdermal patches. Thus, from the above statements, the market segment accounted for the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global scopolamine

North America region is accounted for the largest market share in 2021. The increasing prevalence of cancer-related surgeries, rising awareness of transdermal scopolamine patches among people, product launches and acquisition and collaborations of market players and FDA approvals in the region are the factors drive the market in the period. For instance, according to the National Cancer Institute, in 2020, 1,806,590 new cases were diagnosed, with 606,520 deaths registered of cancer. In addition, in 2021, around 1.9 million were diagnosed, and 608,570 deaths were confirmed of cancer, as per the American Cancer Society. According to the projection by CDC, new cancer cases per year will rise to 29.5 million by 2040. Besides, cancer-related surgeries have also increased with the increasing demand for scopolamine drugs to treat nausea and vomiting.

Moreover, Ingenus Pharmaceuticals, LLC (Riconpharma LLC.) received approval from the United States Food and Drug Administration in December 2021 to manufacture the generic variant of Transderm-Scop (skin patch). As a result, such advancements tend to boost the region's studied market. Thus, from the above statements, the North American region accounted for the largest market share in the forecast period.

Competitive Landscape

Major key players in the scopolamine market are: Baxter International Inc., GlaxoSmithKline plc., Novartis AG, Perrigo Company plc., Caleb Pharmaceuticals, Inc., Myungmoon Pharma Co. LTD., Alchem International, Phytex Australia, Centroflora-Cms, Alkaloids of Australia and Fine Chemical Corporation.

On March 2, 2022, Athira Pharma, Inc. used scopolamine, a novel small molecule candidate for Parkinson's disease dementia, Alzheimer's, and Dementia with Lewy bodies, and ATH-1020, an orally accessible, brain-penetrant small molecule candidate for neuropsychiatric diseases.

Novartis AG:

Overview:

Novartis AG is a multinational pharmaceutical company based out of Switzerland. The company engages in developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develop, manufactures, distributes and sells patented pharmaceuticals and comprises two business units: Novartis Oncology and Novartis Pharmaceuticals. Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments. The Sandoz segment develops, manufactures and markets finished dosage form medicines and intermediary products, including active pharmaceutical ingredients.

Product Portfolio:

Transderm Scop (scopolamine) TRANSDERMAL SYSTEM 1.5 mg: Transderm Scop is a prescription medicine used to treat the symptoms of nausea or vomiting caused by motion sickness or from anesthesia.

The global scopolamine report would provide an access to an approx. 45+ market data table, 40+ figures and 180 pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The increasing prevalence of cancer worldwide is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. Side effects and product discontinuation of scopolamine drugs are expected to hamper market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces
  • 5.2. Supply Chain
  • 5.3. Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Dosage Form

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage Form
    • 7.1.2. Market Attractiveness Index, By Dosage Form
  • 7.2. Tablets*
      • 7.2.1.1. Introduction
      • 7.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Syrups
  • 7.4. Transdermal Patches
  • 7.5. Injections
  • 7.6. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Nausea*
      • 8.2.1.1. Introduction
      • 8.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Motion Sickness

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital pharmacies*
      • 9.2.1.1. Introduction
      • 9.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Retail pharmacies
  • 9.4. Online pharmacies
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage Form
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage Form
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage Form
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage Form
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dosage Form
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Baxter International Inc.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. GlaxoSmithKline plc.
  • 12.3. Novartis AG
  • 12.4. Perrigo Company plc.
  • 12.5. Caleb Pharmaceuticals, Inc.
  • 12.6. Myungmoon Pharma Co. LTD.
  • 12.7. Alchem International
  • 12.8. Phytex Australia
  • 12.9. Centroflora-Cms
  • 12.10. Alkaloids of Australia
  • 12.11. Fine Chemical Corporation

LIST NOT EXHAUSTIVE

13. Global Scopolamine - DataM

  • 13.1. Appendix
  • 13.2. About Us and Applications
  • 13.3. Contact Us